Investigating the Effectiveness of 2 Different Doses of BIOHM FX Probiotic Blend in Improving Digestive Symptoms

Inclusion Criteria: * Age between 18-75 years old, inclusive * Has self-reported moderate digestive symptoms, such as abdominal pain, bloating, flatulence, constipation, or diarrhea. * Has a moderate Gastrointestinal Symptom Rating Scale (GSRS) score between 4-5. * Willingness to refrain from taking probiotics or prebiotics during the study period. * Interested in understanding more about their gut health and the use probiotic products * If taking any OTC or prescription medications for anxiety (e.g. magnesium, anticholinergics, Buspirone, Tricyclics, MAOIs,) or other class of medication for anxiety, must be on a stable dose for at least 4 weeks prior to randomization and throughout the course of the study. * If using any cannabis-containing products, must be on a stable regimen for at least 4 weeks prior to randomization and throughout the course of the study. * If using any nicotine-containing products, must be on a stable regimen for at least 4 weeks prior to randomization and throughout the course of the study. * In good general health at the time of screening (Investigator discretion). * Able to read and understand English. * Able to read, understand, and provide informed consent. * Able to use a personal smartphone device and download Chloe by People Science. * Able to receive shipment of the product at an address within the United States. * Able to complete study assessments over the course of up to 7 weeks. Exclusion Criteria: * Do not have a personal smartphone, internet access, or unwilling to download Chloe. * Concomitant Therapies: * Participants receiving any investigational therapies or treatments within 30 days prior to randomization. * Participants currently taking or have taken antibiotics, probiotics, or prebiotics within the past 4 weeks prior to randomization. * Participants using immunosuppressive medications, systemic steroids, antifungals or other medications known to significantly impact gastrointestinal function or microbiota. * Other Illnesses or Conditions: Participants who have the following comorbidities or gastrointestinal illnesses are excluded: --Participants with a clinical diagnosis of any gastrointestinal illness, including but not limited to: * Inflammatory bowel disease (Crohn's disease, ulcerative colitis) * Gastroesophageal reflux disease (GERD) * Gastric or duodenal ulcers * Celiac disease * Diverticular disease * Chronic pancreatitis * Gastroparesis * Severe liver disease (e.g., cirrhosis, hepatitis, NAFLD acceptable) * Gallbladder disease (e.g., cholecystitis, cholelithiasis) * Gastrointestinal cancer (Colorectal, Intestinal, Stomach, Liver, Gallbladder) * Participants with a known or suspected gastrointestinal infection, such as: * Clostridium difficile infection * Helicobacter pylori infection * Parasitic infections (e.g., Giardia, Cryptosporidium) * Participants with a history of gastrointestinal surgery, excluding appendectomy and cholecystectomy. * Participants with a history of gastrointestinal bleeding or perforation. * Currently diagnosed with Alcohol Abuse and/or Substance Use Disorder * Currently pregnant, planning to become pregnant in the next 1 month, or breastfeeding * Willing to practice a reliable method of contraception for the duration of the study * Any underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes. * Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes.